PCDH18

Summary

PCDH18 (protocadherin 18, HGNC:14268) is a protein-coding gene on chromosome 4q28.3, encoding Protocadherin-18 (Q9HCL0). Potential calcium-dependent cell-adhesion protein.

This gene belongs to the protocadherin gene family, a subfamily of the cadherin superfamily. This gene encodes a protein which contains 6 extracellular cadherin domains, a transmembrane domain and a cytoplasmic tail differing from those of the classical cadherins. Although its specific function is undetermined, the cadherin-related neuronal receptor is thought to play a role in the establishment and function of specific cell-cell connections in the brain.

Source: NCBI Gene 54510 — RefSeq curated summary.

At a glance

• GWAS associations: 16
• Clinical variants (ClinVar): 148 total
• MANE Select transcript: NM_019035

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14268
Approved symbol	PCDH18
Name	protocadherin 18
Location	4q28.3
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1562, PCDH68L
Ensembl gene	ENSG00000189184
Ensembl biotype	protein_coding
OMIM	608287
Entrez	54510

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 6 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000344876, ENST00000412923, ENST00000507846, ENST00000510305, ENST00000511115, ENST00000611581, ENST00000617302, ENST00000620262

RefSeq mRNA: 2 — MANE Select: NM_019035 NM_001300828, NM_019035

CCDS: CCDS34064, CCDS75193

Canonical transcript exons

ENST00000344876 — 4 exons

Exon	Start	End
ENSE00001365509	137528732	137528820
ENSE00001373644	137518918	137521696
ENSE00001376125	137529602	137532494
ENSE00001378073	137528478	137528641

Expression profiles

Bgee: expression breadth ubiquitous, 238 present calls, max score 97.69.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 30.7964 / max 1263.1084, expressed in 1041 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
53983	29.4759	1037
53982	0.9690	358
203342	0.1307	45
53981	0.1273	53
53979	0.0619	21
53980	0.0316	13

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	97.69	gold quality
calcaneal tendon	UBERON:0003701	95.86	gold quality
parietal pleura	UBERON:0002400	95.72	gold quality
mammary duct	UBERON:0001765	95.17	gold quality
ileal mucosa	UBERON:0000331	95.11	gold quality
epithelium of mammary gland	UBERON:0003244	94.99	gold quality
pigmented layer of retina	UBERON:0001782	94.87	gold quality
tibia	UBERON:0000979	94.75	gold quality
endometrium	UBERON:0001295	94.31	gold quality
thoracic mammary gland	UBERON:0005200	93.27	gold quality
mammary gland	UBERON:0001911	93.14	gold quality
placenta	UBERON:0001987	93.08	gold quality
skin of hip	UBERON:0001554	93.05	gold quality
visceral pleura	UBERON:0002401	92.90	gold quality
cauda epididymis	UBERON:0004360	92.06	gold quality
colonic epithelium	UBERON:0000397	92.03	gold quality
tibialis anterior	UBERON:0001385	91.51	silver quality
endothelial cell	CL:0000115	91.24	gold quality
cardiac muscle of right atrium	UBERON:0003379	90.21	gold quality
urethra	UBERON:0000057	90.18	gold quality
layer of synovial tissue	UBERON:0007616	90.10	gold quality
tendon	UBERON:0000043	89.84	gold quality
gall bladder	UBERON:0002110	89.76	gold quality
uterus	UBERON:0000995	89.65	gold quality
seminal vesicle	UBERON:0000998	89.39	gold quality
synovial joint	UBERON:0002217	89.04	gold quality
smooth muscle tissue	UBERON:0001135	88.51	gold quality
adrenal tissue	UBERON:0018303	88.09	gold quality
left ventricle myocardium	UBERON:0006566	88.06	gold quality
subcutaneous adipose tissue	UBERON:0002190	87.81	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-HCAD-30	yes	99.18
E-HCAD-10	yes	57.81
E-ANND-3	yes	20.51
E-CURD-112	yes	9.07

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

125 targeting PCDH18, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-101-3P	99.94	75.03	2230

Literature-anchored findings (GeneRIF, showing 2)

• A homozygous PCDH18 missense mutation (S1006L)from familial hemophagocytic lymphohistiocytosis type 2 patient destabilized the protein structure. (PMID:26739415)
• Our results suggested that PCDH18 was a putative tumor suppressor with epigenetic silencing in colorectal cancer and a potential biomarker for colorectal cancer diagnosis. (PMID:28588296)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	pcdh18b	ENSDARG00000052494
danio_rerio	pcdh18a	ENSDARG00000089805
mus_musculus	Pcdh18	ENSMUSG00000037892
rattus_norvegicus	Pcdh18	ENSRNOG00000009949

Paralogs (61): PCDHB4 (ENSG00000081818), PCDHA6 (ENSG00000081842), PCDHGA2 (ENSG00000081853), PCDHB2 (ENSG00000112852), PCDHB3 (ENSG00000113205), PCDHB5 (ENSG00000113209), PCDHB6 (ENSG00000113211), PCDHB7 (ENSG00000113212), PCDHB15 (ENSG00000113248), PCDH12 (ENSG00000113555), PCDH17 (ENSG00000118946), PCDHB8 (ENSG00000120322), PCDHB10 (ENSG00000120324), PCDHB14 (ENSG00000120327), PCDHB12 (ENSG00000120328), PCDH8 (ENSG00000136099), PCDH10 (ENSG00000138650), PCDH15 (ENSG00000150275), PCDH19 (ENSG00000165194), CDH16 (ENSG00000166589), PCDHB1 (ENSG00000171815), PCDHB9 (ENSG00000177839), PCDHB13 (ENSG00000187372), CDHR4 (ENSG00000187492), PCDHB11 (ENSG00000197479), PCDHGA1 (ENSG00000204956), PCDHA9 (ENSG00000204961), PCDHA8 (ENSG00000204962), PCDHA7 (ENSG00000204963), PCDHA5 (ENSG00000204965), PCDHA4 (ENSG00000204967), PCDHA2 (ENSG00000204969), PCDHA1 (ENSG00000204970), PCDHA13 (ENSG00000239389), PCDHGC3 (ENSG00000240184), PCDHGC5 (ENSG00000240764), PCDHGC4 (ENSG00000242419), PCDHAC2 (ENSG00000243232), PCDHAC1 (ENSG00000248383), PCDHA11 (ENSG00000249158)

Protein

Protein identifiers

Protocadherin-18 — Q9HCL0 (reviewed: Q9HCL0)

All UniProt accessions (5): A0A087WTW3, B4DLR6, Q9HCL0, B4DQ29, D6RIG4

UniProt curated annotations — full annotation on UniProt →

Function. Potential calcium-dependent cell-adhesion protein.

Subunit / interactions. Interacts with DAB1.

Subcellular location. Cell membrane.

Tissue specificity. Expressed in all tissues, with highest expression in lung and ovary.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9HCL0-1	1	yes
Q9HCL0-2	2

RefSeq proteins (2): NP_001287757, NP_061908* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002126	Cadherin-like_dom	Domain
IPR013164	Cadherin_N	Domain
IPR015919	Cadherin-like_sf	Homologous_superfamily
IPR020894	Cadherin_CS	Conserved_site
IPR050174	Protocadherin/Cadherin-CA	Family

Pfam: PF00028, PF08266

UniProt features (69 total): strand 30, helix 8, domain 6, glycosylation site 6, region of interest 5, turn 5, compositionally biased region 3, topological domain 2, signal peptide 1, chain 1, splice variant 1, transmembrane region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
6VFR	X-RAY DIFFRACTION	2.79

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HCL0-F1	68.89	0.39

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (6): 103, 269, 420, 559, 583, 641

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 143 (showing top): FREAC2_01, BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN, RORA1_01, ROVERSI_GLIOMA_COPY_NUMBER_UP, CHX10_01, AAAYRNCTG_UNKNOWN, CHANDRAN_METASTASIS_DN, CAGCTG_AP4_Q5, SHEPARD_BMYB_MORPHOLINO_DN, GOBP_CELL_CELL_ADHESION, BRN2_01, TGCTGAY_UNKNOWN, KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN

GO Biological Process (3): cell adhesion (GO:0007155), homophilic cell-cell adhesion (GO:0007156), brain development (GO:0007420)

GO Molecular Function (3): calcium ion binding (GO:0005509), cell adhesion molecule binding (GO:0050839), protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular process	1
cell-cell adhesion	1
central nervous system development	1
animal organ development	1
head development	1
metal ion binding	1
protein binding	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

882 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PCDH18	DIPK2A	Q8NDZ4	762
PCDH18	LYSMD3	Q7Z3D4	458
PCDH18	PKHD1	P08F94	437
PCDH18	TM4SF1	P30408	424
PCDH18	SIX1	Q15475	412
PCDH18	KLK2	P20151	409
PCDH18	NKX3-1	Q99801	401
PCDH18	LPAR1	P78351	400
PCDH18	LCK	P06239	399
PCDH18	MDM4	O15151	396
PCDH18	KLK3	P07288	389
PCDH18	RNASEL	Q05823	377
PCDH18	TGFBR2	P37173	376
PCDH18	SCN1A	P35498	373
PCDH18	FGFR1	P11362	373

IntAct

26 interactions, top by confidence:

A	B	Type	Score
BRK1	CYFIP1	psi-mi:“MI:0914”(association)	0.640
PCDH18	UBQLN1	psi-mi:“MI:0915”(physical association)	0.560
PCDHGB1	FAM171A2	psi-mi:“MI:0914”(association)	0.530
PCDH18	HNRNPL	psi-mi:“MI:0915”(physical association)	0.400
	HAX1	psi-mi:“MI:0914”(association)	0.350
TEX101	MAP4K4	psi-mi:“MI:0914”(association)	0.350
ATG5	IGKV1-5	psi-mi:“MI:0914”(association)	0.350
CACNA1C	IGLL5	psi-mi:“MI:0914”(association)	0.350
CACNA1C	CACNB4	psi-mi:“MI:0914”(association)	0.350
CACNA1C	SNRPGP15	psi-mi:“MI:0914”(association)	0.350
CACNA1C	DISP2	psi-mi:“MI:0914”(association)	0.350
HCN1	POTEF	psi-mi:“MI:0914”(association)	0.350
SPSB4	CCDC85C	psi-mi:“MI:0914”(association)	0.350
RYK	TNFRSF10B	psi-mi:“MI:0914”(association)	0.350
CDH17	TNFSF9	psi-mi:“MI:0914”(association)	0.350
PCDH10	SHMT1	psi-mi:“MI:0914”(association)	0.350
PCDH20	CAPN5	psi-mi:“MI:0914”(association)	0.350
UPK2	IFT56	psi-mi:“MI:0914”(association)	0.350
PCDH18	UBQLN1	psi-mi:“MI:0915”(physical association)	0.000
UBQLN1	PCDH18	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (27): PCDH18 (Affinity Capture-MS), PCDH18 (Proximity Label-MS), PCDH18 (Synthetic Lethality), PCDH18 (Affinity Capture-MS), PCDH18 (Two-hybrid), PCDH18 (Proximity Label-MS), PCDH18 (Affinity Capture-MS), PCDH18 (Affinity Capture-MS), PCDH18 (Affinity Capture-MS), PCDH18 (Affinity Capture-MS), PCDH18 (Affinity Capture-MS), PCDH18 (Affinity Capture-MS), PCDH18 (Affinity Capture-MS), PCDH18 (Proximity Label-MS), PCDH18 (Affinity Capture-MS)

ESM2 similar proteins: A7MB46, F8W3X3, O14917, O35902, O54800, O97799, P05622, P16234, P20786, P26618, P26619, P32926, P35546, P55286, P55289, P79749, P97291, Q05030, Q08DJ5, Q13634, Q14126, Q28889, Q5RJH3, Q68SP4, Q6KEQ9, Q6W3B0, Q6WXV7, Q6WYY1, Q6X862, Q71M42, Q7TMD7, Q7TSF0, Q7YRU7, Q80TF3, Q86SJ6, Q8AXC6, Q8AXC7, Q8BIZ0, Q8N6Y1, Q8TAB3

Diamond homologs: A7MB46, D3ZE55, F8W3X3, O14917, O55134, O60330, O88689, O95206, Q5DRA2, Q5DRA3, Q5DRA4, Q5DRA5, Q5DRA6, Q5DRA7, Q5DRA8, Q5DRA9, Q5DRB0, Q5DRB1, Q5DRB2, Q5DRB3, Q5DRB4, Q5DRB5, Q5DRB6, Q5DRB7, Q5DRB8, Q5DRB9, Q5DRC0, Q5DRC1, Q5DRC2, Q5DRC6, Q5DRD3, Q5DRD6, Q5DRE0, Q5DRE1, Q5DRE3, Q5DRE4, Q5DRE5, Q5DRE6, Q5DRE7, Q5DRE8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

148 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	137
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

614 predictions. Top by Δscore:

Variant	Effect	Δscore
4:137528473:CTTA:C	donor_loss	1.0000
4:137528474:TTA:T	donor_loss	1.0000
4:137528475:TA:T	donor_loss	1.0000
4:137528476:A:AC	donor_gain	1.0000
4:137528476:A:C	donor_loss	1.0000
4:137528477:C:CA	donor_loss	1.0000
4:137528477:C:CC	donor_gain	1.0000
4:137528477:CCTG:C	donor_gain	1.0000
4:137528637:CATAT:C	acceptor_gain	1.0000
4:137528638:ATAT:A	acceptor_gain	1.0000
4:137528639:TAT:T	acceptor_gain	1.0000
4:137528639:TATC:T	acceptor_loss	1.0000
4:137528640:AT:A	acceptor_gain	1.0000
4:137528641:TCTGG:T	acceptor_loss	1.0000
4:137528642:C:CC	acceptor_gain	1.0000
4:137528642:C:CG	acceptor_loss	1.0000
4:137528643:T:A	acceptor_loss	1.0000
4:137528650:A:AC	acceptor_gain	1.0000
4:137528650:A:C	acceptor_gain	1.0000
4:137528656:C:CT	acceptor_gain	1.0000
4:137528726:TCATA:T	donor_loss	1.0000
4:137528727:CATA:C	donor_loss	1.0000
4:137528728:ATAC:A	donor_loss	1.0000
4:137528729:TACC:T	donor_loss	1.0000
4:137528731:C:CG	donor_loss	1.0000
4:137528818:CTG:C	acceptor_gain	1.0000
4:137529598:TTAC:T	donor_loss	1.0000
4:137529599:TA:T	donor_loss	1.0000
4:137529600:ACCTC:A	donor_loss	1.0000
4:137528640:ATCT:A	acceptor_gain	0.9900

AlphaMissense

7537 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:137531358:G:T	P244H	1.000
4:137531367:T:A	D241V	1.000
4:137531367:T:G	D241A	1.000
4:137531436:G:T	A218D	1.000
4:137531472:C:G	R206P	1.000
4:137531694:T:G	D132A	1.000
4:137521054:A:G	L1128P	0.999
4:137521644:G:C	C931W	0.999
4:137521645:C:G	C931S	0.999
4:137521646:A:G	C931R	0.999
4:137521646:A:T	C931S	0.999
4:137521672:C:G	C922S	0.999
4:137521673:A:G	C922R	0.999
4:137521673:A:T	C922S	0.999
4:137530731:A:T	V453D	0.999
4:137530951:C:G	A380P	0.999
4:137531269:C:G	D274H	0.999
4:137531274:T:C	D272G	0.999
4:137531274:T:G	D272A	0.999
4:137531275:C:G	D272H	0.999
4:137531280:G:T	A270D	0.999
4:137531366:G:C	D241E	0.999
4:137531366:G:T	D241E	0.999
4:137531367:T:C	D241G	0.999
4:137531368:C:G	D241H	0.999
4:137531369:A:C	N240K	0.999
4:137531369:A:T	N240K	0.999
4:137531370:T:A	N240I	0.999
4:137531375:G:C	D238E	0.999
4:137531375:G:T	D238E	0.999

dbSNP variants (sampled 300 via entrez): RS1000030683 (4:137519356 T>A), RS1000046391 (4:137522412 G>A), RS1000078640 (4:137523951 A>C), RS1000271264 (4:137528740 C>A,T), RS10004843 (4:137523207 C>G,T), RS10006580 (4:137528658 C>A,G,T), RS1000845548 (4:137528969 C>A,T), RS10010962 (4:137524975 C>A,G), RS1001106512 (4:137522506 C>A), RS1001361633 (4:137528697 T>C), RS1001706073 (4:137532246 T>C), RS1001726808 (4:137533749 C>T), RS10018837 (4:137528529 A>G), RS1001961231 (4:137527274 T>C), RS1002000071 (4:137533595 T>C)

Disease associations

OMIM: gene MIM:608287 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

16 associations (top):

Study	Trait	p-value
GCST001531_7	Temperament	2.000000e-06
GCST001762_942	Obesity-related traits	8.000000e-07
GCST001854_2	Retinopathy in non-diabetics	5.000000e-06
GCST002034_3	Adverse response to radiation therapy	1.000000e-06
GCST002826_11	Urate levels (BMI interaction)	9.000000e-07
GCST002938_36	Copper levels	7.000000e-06
GCST004703_4	Obsessive-compulsive disorder or autism spectrum disorder	4.000000e-06
GCST004735_31	Epstein-Barr virus copy number in lymphoblastoid cell lines	1.000000e-06
GCST004824_8	P wave terminal force	3.000000e-09
GCST007927_17	Medication use (beta blocking agents)	1.000000e-09
GCST007930_49	Medication use (agents acting on the renin-angiotensin system)	4.000000e-09
GCST009363_49	Triglyceride levels x short total sleep time interaction (2df test)	1.000000e-09
GCST010002_15	Refractive error	5.000000e-11
GCST010774_20	Essential hypertension (time to event)	4.000000e-08
GCST010988_78	Adult body size	3.000000e-17
GCST010989_245	Body size at age 10	6.000000e-10

EFO canonical traits (10, from GWAS)

EFO ID	Trait name
EFO:0004825	temperament and character inventory
EFO:0003939	energy intake
EFO:0004340	body mass index
EFO:0004531	urate measurement
EFO:0008379	P wave terminal force measurement
EFO:0009929	Beta blocking agent use measurement
EFO:0009931	Agents acting on the renin-angiotensin system use measurement
EFO:0004530	triglyceride measurement
EFO:0004918	age at diagnosis
EFO:0009819	comparative body size at age 10, self-reported

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

53 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression	5
trichostatin A	affects cotreatment, decreases expression	3
sodium arsenite	increases abundance, decreases expression	3
Air Pollutants	increases expression, decreases expression, affects cotreatment, increases abundance	3
Estradiol	affects cotreatment, decreases expression	3
Particulate Matter	decreases expression, increases abundance	3
bisphenol A	decreases methylation, increases expression	2
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, decreases expression	2
mercuric bromide	decreases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Aflatoxin B1	decreases expression, decreases methylation	2
p-Chloromercuribenzoic Acid	decreases expression, affects cotreatment	2
bisphenol F	affects cotreatment, increases methylation	1
methylmercuric chloride	decreases expression	1
alpha-pinene	affects cotreatment, increases expression, increases abundance	1
2-methyl-4-isothiazolin-3-one	increases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
methacrylaldehyde	increases expression, increases abundance, affects cotreatment	1
diallyl trisulfide	decreases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	increases expression, affects cotreatment, decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
pentabromodiphenyl ether	decreases expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
incobotulinumtoxinA	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.